Answers are grounded in this paper and cite their sources.
Cross-sectional analysis shows significant association between NUCB2 variants and colorectal cancer, suggesting potential biomarkers.
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. Recent evidence suggests a potential role for the neuropeptide nesfatin-1, encoded by the NUCB2 gene, in cancer development. This study aimed to analyze the association between the rs1330 and rs757081 variants of NUCB2 and CRC in a Mexican population. A total of 780 individuals were included in a cross-sectional study: 397 patients with CRC and 383 healthy controls. The CT and TT genotypes of rs1330 were significantly associated with CRC (odds ratio [OR] = 0.6127, P = 0.0029; OR = 2.6574, P = 0.000, respectively), as were the CG and GG genotypes of rs707581 (OR = 0.6825, P = 0.019; OR = 2.6975, P = 0.000, respectively). Hardy-Weinberg equilibrium was not met for either variant (P = 0.000). Haplotype analysis indicated that the T/G haplotype conferred increased risk, while C/C had a protective effect. These findings support a potential role for NUCB2 variants as biomarkers for CRC susceptibility in the Mexican population.
No takes yet. Share an insight, caveat, or question.
Macías‐Gómez et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: